Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates.
Ratoe SurayaMotoko TachiharaTatsuya NaganoYoshihiro NishimuraKazuyuki KobayashiPublished in: Cancer management and research (2022)
Non-small-cell lung cancer (NSCLC) is a major health burden, and novel therapeutic options are needed to help solve this problem. One such option is immunotherapy, which targets immune checkpoint molecules that inhibit cancer cells, decreasing immune system activation, for example, immunotherapies target PD-1, its ligand PD-L1, and CTLA-4. There have been major advances in the development of agents that inhibit these molecules, called immune checkpoint inhibitors, and several of them are already approved for usage in NSCLC patients, especially in advanced stages. In this review, the reasons why immune checkpoint inhibitors could be beneficial and the clinical results of studies using these drugs for advanced or recurrent NSCLC patients are discussed, as is the safety profile of the drugs.
Keyphrases
- end stage renal disease
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- healthcare
- current status
- peritoneal dialysis
- mental health
- stem cells
- mesenchymal stem cells
- cell therapy
- young adults
- climate change
- bone marrow
- patient reported
- risk assessment
- single cell
- brain metastases